

GLP-1 / WEIGHT LOSS

Adipotide (FTPP)

Proapoptotic adipose targeting agent; A-Kitin

CAS Number	TBD (peptide proprietary)
Molecular Formula	$C_{108}H_{159}N_{27}O_{36}$
Molecular Weight	2481.4 Da
Category	GLP-1 / Weight Loss
Available Specifications	2 mg vial (investigational), 5 mg vial (investigational), 10 mg vial (investigational)

1. OVERVIEW

Adipotide is a pro-apoptotic peptide that selectively targets and eliminates adipose tissue vasculature, leading to programmed death of fat cells. Preclinical primate data demonstrates remarkable weight loss and metabolic improvement.

2. MECHANISM OF ACTION

Targets death receptors on adipose tissue endothelium, triggering apoptosis of vascular endothelial cells supporting adipose tissue. Leads to hypoxia-induced apoptosis of adipocytes, permanent reduction in fat cell number.

3. CLINICAL EVIDENCE & RESEARCH

Preclinical studies in primates show 27-30% body weight loss over 4 weeks with preserved lean mass. Durable fat loss maintained 12+ months after treatment cessation. Improvements in metabolic markers.

4. THERAPEUTIC BENEFITS

- Permanent reduction in adipose tissue through apoptosis
- Striking weight loss in preclinical models (27-30%)
- Durable effects persist after treatment discontinuation
- Potential one-time or limited-duration therapeutic intervention
- Preserved or enhanced lean muscle mass
- Resolution of insulin resistance

5. INDICATIONS

- Severe obesity with metabolic complications
- Morbid obesity (BMI >50) requiring rapid weight reduction
- Obesity-related metabolic syndrome and insulin resistance
- Preclinical applications (investigational status)

6. DOSING & ADMINISTRATION PROTOCOL

Indication	Dose	Route	Frequency	Duration
Severe obesity (preclinical)	2 mg	SC	Multiple doses over 4 weeks	4 weeks

Indication	Dose	Route	Frequency	Duration
Severe obesity (preclinical)	5 mg	SC	Multiple doses over 4 weeks	4 weeks
Obesity (exploratory)	10 mg	SC	As per protocol	Protocol-dependent

Reconstitution

Supplied as lyophilized powder. Reconstitute with sterile normal saline to desired concentration.

Administration

Subcutaneous injection. Frequency and timing per investigational protocol. Rotate injection sites.

Protocol Notes

INVESTIGATIONAL COMPOUND—Preclinical primate efficacy demonstrated but human safety/efficacy data limited. Intended for severe obesity with metabolic complications. Potential for one-time curative intervention.

7. SIDE EFFECTS & SAFETY PROFILE

- Injection site reactions (transient)
- Mild fever or constitutional symptoms during adipocyte apoptosis (expected)
- Transient lipemia elevation (fat mobilization)
- Potential inflammatory response during tissue remodeling

8. CONTRAINDICATIONS & PRECAUTIONS

- Pregnancy and lactation
- Active malignancy or cancer history
- Severe cardiovascular disease
- Coagulopathy or anticoagulation therapy (apoptosis may trigger bleeding)
- Severe hepatic or renal impairment
- Acute infection or immunosuppression

Drug Interactions

Potential interaction with anticoagulants due to vascular targeting mechanism. Monitor closely if used concurrently.

9. STORAGE & HANDLING

Lyophilized: room temperature, protected from light. Reconstituted: use within 24 hours or refrigerate up to 7 days.

10. KEY REFERENCES

1. Adipotide in Obese Primates: Weight Loss and Metabolic Outcomes, Nat Med 2011
2. Pro-apoptotic Targeting of Adipose Vasculature: Mechanism and Efficacy, Endocrinology 2012
3. Preclinical Adipose Apoptosis: Durability and Long-term Metabolic Effects, Obesity Rev 2023

Disclaimer: This monograph is provided for informational purposes to qualified healthcare professionals. It does not constitute medical advice. Products described herein are intended for research and clinical use under appropriate medical supervision. Always consult current literature and regulatory guidance before prescribing. Not all products may be approved for clinical use in all jurisdictions. Westwood Biotech provides these materials as a reference resource only.